$0.39
Live
0.0%
Downside
Day's Volatility :12.36%
Upside
12.36%
49.49%
Downside
52 Weeks Volatility :95.44%
Upside
90.97%
Period | Universe Pharmaceuticals Inc | Index (Russel 2000) |
---|---|---|
3 Months | -89.32% | 0.0% |
6 Months | -78.69% | 0.0% |
1 Year | -47.39% | 0.0% |
3 Years | -97.04% | -23.0% |
Market Capitalization | 9.7M |
Book Value | $7.34 |
Earnings Per Share (EPS) | -5.09 |
Profit Margin | -69.41% |
Operating Margin TTM | -13.51% |
Return On Assets TTM | -5.65% |
Return On Equity TTM | -50.22% |
Revenue TTM | 26.7M |
Revenue Per Share TTM | 7.35 |
Quarterly Revenue Growth YOY | -30.2% |
Gross Profit TTM | 21.9M |
EBITDA | -4.9M |
Diluted Eps TTM | -5.09 |
Quarterly Earnings Growth YOY | -0.82 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 28.5M | - |
Net Income | 7.6M | - |
Net Profit Margin | 26.66% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 33.2M | ↑ 16.54% |
Net Income | 7.6M | ↓ 0.68% |
Net Profit Margin | 22.73% | ↓ 3.93% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 30.7M | ↓ 7.6% |
Net Income | 7.6M | ↑ 0.09% |
Net Profit Margin | 24.62% | ↑ 1.89% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 48.0M | ↑ 56.27% |
Net Income | 11.3M | ↑ 49.77% |
Net Profit Margin | 23.59% | ↓ 1.03% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 40.1M | ↓ 16.34% |
Net Income | -8.7M | ↓ 177.18% |
Net Profit Margin | -21.76% | ↓ 45.35% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 32.3M | ↓ 19.52% |
Net Income | -6.2M | ↓ 29.46% |
Net Profit Margin | -19.08% | ↑ 2.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 15.9M | - |
Net Income | -10.5M | - |
Net Profit Margin | -65.67% | - |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 18.5M | - |
Net Income | -715.4K | - |
Net Profit Margin | -3.87% | - |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.8M | ↓ 25.05% |
Net Income | -5.4M | ↑ 661.45% |
Net Profit Margin | -39.36% | ↓ 35.49% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 12.9M | ↓ 6.92% |
Net Income | -13.1M | ↑ 140.5% |
Net Profit Margin | -101.68% | ↓ 62.32% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 28.1M | - |
Total Liabilities | 18.4M | - |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 17.8M | ↓ 36.48% |
Total Liabilities | 5.5M | ↓ 70.36% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 28.8M | ↑ 61.49% |
Total Liabilities | 8.0M | ↑ 46.74% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 70.1M | ↑ 143.52% |
Total Liabilities | 11.2M | ↑ 40.11% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 59.5M | ↓ 15.12% |
Total Liabilities | 13.1M | ↑ 16.83% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 53.3M | ↓ 10.5% |
Total Liabilities | 13.8M | ↑ 5.01% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 59.5M | ↑ 0.0% |
Total Liabilities | 13.1M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.4M | ↑ 18.19% |
Total Liabilities | 23.2M | ↑ 77.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.4M | ↑ 0.0% |
Total Liabilities | 23.2M | ↑ 0.0% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.3M | ↓ 24.27% |
Total Liabilities | 13.8M | ↓ 40.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 53.3M | ↑ 0.0% |
Total Liabilities | 13.8M | ↑ 0.0% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 49.4M | ↓ 7.24% |
Total Liabilities | 22.7M | ↑ 64.94% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.5M | - |
Investing Cash Flow | -145.1K | - |
Financing Cash Flow | -4.9M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 13.2M | ↑ 196.34% |
Investing Cash Flow | -86.0K | ↓ 40.71% |
Financing Cash Flow | -16.0M | ↑ 225.64% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.1M | ↓ 53.69% |
Investing Cash Flow | -51.8K | ↓ 39.79% |
Financing Cash Flow | 470.1K | ↓ 102.94% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 133.62% |
Investing Cash Flow | -27.1M | ↑ 52141.32% |
Financing Cash Flow | 26.6M | ↑ 5554.07% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.3M | ↓ 36.17% |
Investing Cash Flow | -3.9M | ↓ 85.56% |
Financing Cash Flow | 3.3M | ↓ 87.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↓ 160.72% |
Investing Cash Flow | -1.9M | ↑ 0.0% |
Financing Cash Flow | 1.7M | ↓ 8448.6% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↑ 112.66% |
Investing Cash Flow | -323.0 | ↓ 99.98% |
Financing Cash Flow | 3.3M | ↑ 100.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.4M | ↓ 130.37% |
Investing Cash Flow | -323.0 | ↑ 0.0% |
Financing Cash Flow | 1.0M | ↓ 68.83% |
Sell
Neutral
Buy
Universe Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Universe Pharmaceuticals Inc | 64.27% | -78.69% | -47.39% | -97.04% | -98.54% |
Neurocrine Biosciences Inc. | 0.22% | -11.71% | 9.36% | 13.47% | 21.32% |
Haleon Plc Spon Ads | -5.08% | 20.69% | 22.01% | 36.17% | 36.17% |
Zoetis Inc. | -0.16% | 32.8% | 16.08% | -7.35% | 52.85% |
Viatris Inc. | 2.53% | 4.53% | 31.84% | -16.06% | -28.03% |
Catalent, Inc. | 0.9% | 7.56% | 42.8% | -54.43% | 23.98% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Universe Pharmaceuticals Inc | NA | NA | NA | 0.0 | -0.5 | -0.06 | NA | 7.34 |
Neurocrine Biosciences Inc. | 35.55 | 35.55 | 0.27 | 4.54 | 0.16 | 0.12 | NA | 24.87 |
Haleon Plc Spon Ads | 32.52 | 32.52 | 1.5 | 0.39 | 0.07 | 0.04 | 0.02 | 1.82 |
Zoetis Inc. | 37.9 | 37.9 | 2.64 | 5.83 | 0.49 | 0.14 | 0.01 | 10.94 |
Viatris Inc. | 224.4 | NA | 0.07 | 2.67 | -0.03 | 0.03 | 0.04 | 16.36 |
Catalent, Inc. | 211.02 | NA | 3.02 | 0.2 | -0.25 | 0.0 | NA | 19.91 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Universe Pharmaceuticals Inc | NA | $9.7M | -98.54% | NA | -69.41% |
Neurocrine Biosciences Inc. | Buy | $11.9B | 21.32% | 35.55 | 16.0% |
Haleon Plc Spon Ads | Buy | $45.6B | 36.17% | 32.52 | 9.66% |
Zoetis Inc. | Buy | $87.6B | 52.85% | 37.9 | 26.29% |
Viatris Inc. | Hold | $14.0B | -28.03% | 224.4 | -4.24% |
Catalent, Inc. | Hold | $10.9B | 23.98% | 211.02 | -23.81% |
Insights on Universe Pharmaceuticals Inc
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 89.7%
In the last 3 years, Universe Pharmaceuticals Inc has experienced a drawdown of -97.0%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 42.6%
UBS Group AG
Organization | Universe Pharmaceuticals Inc |
Employees | 225 |
CEO | Mr. Gang Lai |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.39
-6.25%
Invesco Bulletshares 2025 Hi
$0.39
-6.25%
Schwab International Dividend Equity Etf
$0.39
-6.25%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.39
-6.25%
Lightpath Technologies Inc
$0.39
-6.25%
Vaneck Vectors Global Alternative Energy Etf
$0.39
-6.25%
First Trust Flexible Municipal High Income Etf
$0.39
-6.25%
Drx Dly Reg Bank Bull 3x
$0.39
-6.25%
Graniteshares 2x Long Pltr Daily Etf
$0.39
-6.25%